SpotitEarly Partners with Fox Chase Cancer Center to Validate AI-Canine Breath-Based Cancer Detection Technology
核心洞察
SpotitEarly (搜索) has formed a strategic partnership with Fox Chase Cancer Center to conduct multi-year clinical trials evaluating its breath-based cancer detection test in lung cancer patients.
The collaboration combines SpotitEarly (搜索)'s proprietary LUCID bio-AI hybrid platform, which uses trained canines and artificial intelligence to identify cancer odor signatures in breath samples.
Previous clinical studies involving over 1,300 participants demonstrated the platform's overall sensitivity of approximately 94% across four common cancers with strong early-stage performance.
SpotitEarly (搜索), an early cancer detection startup utilizing artificial intelligence and trained canines to identify cancer odor signatures in breath samples, has announced a strategic partnership with Fox Chase Cancer Center to advance clinical validation of its breakthrough detection technology. The collaboration includes plans for multi-year clinical trials and represents a significant step toward commercializing the company's non-invasive screening approach.
Clinical Trial Framework
Under the master research collaboration agreement, Fox Chase Cancer Center will lead a multi-year, investigator-initiated clinical trial evaluating the performance of SpotitEarly (搜索)'s exhaled-breath test in patients undergoing standard-of-care evaluation for suspected lung cancer. The collaboration combines direct research funding with a long-term strategic partnership model designed to align incentives and accelerate clinical translation.
The partnership structure includes potential expansion to additional cancer indications and future applications beyond the initial lung cancer program, providing a framework for broader clinical development.
LUCID Bio-AI Hybrid Platform
SpotitEarly (搜索)'s proprietary LUCID bio-AI hybrid platform combines artificial intelligence and machine learning with trained canine scent detection, using integrated sensors to continuously monitor canine behavioral and physiological signals. These signals are translated into a standardized, repeatable approach for identifying cancer-associated signals in breath, enabling non-invasive screening focused on earlier detection when treatment options are most effective.
The test uses a simple breath collection process based on a face mask kit and is developed by a multidisciplinary team spanning medicine, data science, engineering, and laboratory operations.
Clinical Performance Data
In a completed prospective, double-blind clinical study involving more than 1,300 participants, the platform demonstrated overall sensitivity of approximately 94% across four common cancers, with strong performance in early-stage disease. This clinical evidence supports the potential for the technology to improve early detection outcomes across multiple cancer types.
Strategic Partnership Expansion
The Fox Chase collaboration follows SpotitEarly (搜索)'s partnership announcement with Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, which included plans for joint clinical trials announced in July. The pace and distinction of these U.S.-based partnerships since entering the market in May highlight growing confidence in SpotitEarly's approach to early cancer detection.
"At Fox Chase, we are committed to pushing the boundaries of cancer research through bold and collaborative partnerships," said Sangeeta Bardhan Cook, PhD, MBA, Chief Innovation Officer at Fox Chase Cancer Center. "SpotitEarly (搜索) brings an unconventional yet scientifically promising approach to early detection, and we see tremendous potential in their innovative product and technology when combined with our robust clinical expertise. Together, we will open new doors to earlier diagnoses and, ultimately, better outcomes for patients."
Company Leadership Perspective
Shlomi Madar, PhD, CEO of SpotitEarly (搜索), emphasized the strategic importance of the Fox Chase partnership: "Working with Fox Chase Cancer Center was a natural next step for our organization as we continue to grow our footprint in the states. As a leader in cancer research, their team will provide us with access to a vast network of physicians and resources to collaborate on groundbreaking clinical trials and treatments, moving forward our mission of increasing accessibility to early cancer detection technology for millions."
SpotitEarly (搜索) has dedicated a portion of its company equity to Fox Chase Cancer Center, representing its commitment to collaboration and advancing early cancer detection research. Subject to regulatory approval, SpotitEarly aims to broaden access to cancer screening, improve early detection, and support better clinical outcomes.